Original Source(s)
Related Content
ESMO26: Toni Choueiri, MD, on KEYNOTE-564
Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.
November 17, 2026
-
1 min
What Your Patients Need to Know for Medicare Open Enrollment
The annual Medicare open enrollment period runs October 15 to December 7 this year, giving adults ages 65 and older the opportunity to review and possibly change their healthcare coverage.